title: [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
abstract: The objective of this study was to evaluate the efficacy and safety of low-dose docetaxel, estramustine and dexamethasone combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC). Sixty-nine patients with HRPC were enrolled. Docetaxel was given at a dose of 25 mg/m(2) on days 1 and 8 every 3 weeks, oral estramustine 280 mg twice daily on days 1 to 3 and 8 to 10, and oral dexamethasone 1 mg daily throughout the course. Cycles were repeated every 21 days. Treatment was continued until disease progression or excessive toxicity. Patients were evaluated for response and toxicity. Patients received a median of eleven cycles (range : 1-25). Prostatic-specific antigen (PSA) was decreased greater than 50% in 53 (77%) out of 69 patients and median duration of PSA response was 10.2 months. Median time to progression and overall survival 10.2 and 24 months, respectively. Grade 1-2 fatigue was the most common toxicity observed in 10 (15%) patients. Grade 3-4 toxicities were observed in five (7%) patients (2 thrombosis, 2 bilirubin elevation, and 1 aspartate transaminase/alanine transaminase elevation). Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy is an effective and well tolerated treatment for Japanese HRPC patients.
authors.affiliation: Department of Urology, Yokosuka Kyosai Hospital.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Yokonishi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Ito
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Susumu
authors.initials: S
authors.lastname: Umemoto
authors.forename: Kimito
authors.initials: K
authors.lastname: Osaka
authors.forename: Masafumi
authors.initials: M
authors.lastname: Nakamura
authors.forename: Tatsuaki
authors.initials: T
authors.lastname: Onuki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Komiya
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Ohgo
authors.forename: Naoki
authors.initials: N
authors.lastname: Sakai
authors.forename: Sumio
authors.initials: S
authors.lastname: Noguchi
authors.forename: Hiroichi
authors.initials: H
authors.lastname: Kishi
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yokomizo
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawai
authors.forename: Kazuto
authors.initials: K
authors.lastname: Okajima
authors.forename: Takehiro
authors.initials: T
authors.lastname: Tajiri
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujikawa
authors.forename: Junichi
authors.initials: J
authors.lastname: Ohta
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yumura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Moriyama
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D003907:Dexamethasone; D017430:Prostate-Specific Antigen